Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?

Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens

(2021) Jacob E Choby et al.   LANCET INFECTIOUS DISEASES

New Perspectives on Antimicrobial Agents: Cefiderocol

(2021) Erin K. McCreary et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment of Patients with Serious Infections Due to Carbapenem‐resistant Acinetobacter baumannii : How Viable are the Current Options?

(2021) J Nicholas O’Donnell et al.   PHARMACOTHERAPY

Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?

(2020) Ryan K. Shields   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cefiderocol: the Trojan horse has arrived but will Troy fall?

(2020) Emily L Heil et al.   LANCET INFECTIOUS DISEASES

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

(2020) Matteo Bassetti et al.   LANCET INFECTIOUS DISEASES

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

(2020) Richard G Wunderink et al.   LANCET INFECTIOUS DISEASES

US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)

(2020) Shabnam Naseer et al.   CLINICAL INFECTIOUS DISEASES

Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection

(2019) Victor I. Band et al.   Nature Microbiology